Tibotec's Intelence approved in Europe
This article was originally published in Scrip
Executive Summary
Tibotec's Intelence (etravirine) has been approved by the European Commission for the treatment of HIV-1 in antiretroviral treatment-experienced adults. Tibotec said that Intelence will be available across the EU, but said that the timing of its launch would be dependent on pricing and reimbursement negotiations in individual countries. Intelence, a non-nucleoside reverse transcriptase inhibitor, was approved in the US in January and received a positive opinion from the EU's CHMP in June (Scrip Online, June 27th, 2008).